

CS/BSE/NSE/2019-2020  
February 4, 2020

To  
The General Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001  
Scrip Code: 530239

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
Scrip Symbol: SUVEN

Dear Sir/Madam,

**Sub: Clarification on Price Movement**

**Ref: 1) BSE L/SURV/ONL/PV/ZS/2019-2020/1024, your email dated February 3, 2020**

**2) NSE letter No: NSE/CM/Surveillance/9040, dated: February 4, 2020**

.....  
We write to inform that our company has been notifying NSE & BSE all the information which comes under the purview of Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time.

In this context, we would like to draw your attention to our Company's recent announcement on Record Date (i.e., 22<sup>nd</sup> January, 2020) for issue and allotment of equity shares in Suven Pharmaceuticals Ltd (Resulting Company) in the ratio of 1:1 to the equity shareholders of Suven Life Sciences Ltd (Demerged Company) pursuant Scheme of Arrangement (Demerger) as approved by NCLT, Hyderabad Bench through its order dated 6<sup>th</sup> January, 2020 which became operational w.e.f. 9<sup>th</sup> January, 2020.

At this point of time we do not have any material event due for notification to the stock exchanges under Regulation 30 of SEBI LODR Regulations other than Q3 Results which will be released post approval in the ensuing Board meeting of our Company. The date of Board meeting will be notified separately in accordance with the SEBI LODR Regulations.

We request you to disseminate this clarification on your website for information of general public, which is also being uploaded on our Company's website.

Thanking You,

Yours faithfully,

For **Suven Life Sciences Limited**



**Shrenik Soni**

Company Secretary

## **Suven Life Sciences Limited**